KIT and gastrointestinal stromal tumor: In the same vein, we are eager for the INSIGHT trial to start, assessing ripretinib versus sunitinib in the second line, dedicated to a specific population of patients with GIST bearing a mutation in KIT exon 11 associated with a mutation in KIT exon 17 (NCT05734105).